35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience

Abstract Frontline high-dose therapy (HDT) is, in 2025, the standard of care for patients with multiple myeloma (MM) who are eligible for autologous stem cell transplantation (ASCT). Prior to high-dose melphalan, induction therapy with quadruplet combinations is also proposed systematically when pos...

Повний опис

Бібліографічні деталі

Автори:	Philippe Moreau, Cyrille Hulin, Alexis Talbot, Hélène Demarquette, Léo Caillot, Thomas Chalopin, Arthur Bobin, Salomon Manier, Xavier Leleu, Lionel Karlin, Denis Caillot, Cécile Sonntag, Pierre Feugier, Murielle Roussel, Romain Gounot, Margaret Macro, Mohamad Mohty, Laurent Garderet, Mourab Tiab, Frédérique Orsini-Piocelle, Laure Vincent, Nathalie Meuleman, Jean Fontan, Lidia Montes, Marie-Christiane Vekemans, Martine Escoffre-Barbe, Jean-Richard Eveillard, Jean-Marc Schiano de Colella, Jérôme Lambert, Jean-Yves Mary, Jean-Paul Fermand, Bertrand Arnulf, Jill Corre, Hervé Avet-Loiseau, Thierry Facon, Jean-Luc Harousseau, Cyrille Touzeau, Aurore Perrot
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Nature Publishing Group 2025-10-01
Серія:	Blood Cancer Journal
Онлайн доступ:	https://doi.org/10.1038/s41408-025-01387-6
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!